Interview with Hoon Han, President, Histostem
After spending a large part of your career as a university professor, what drove you to create your own company, Histostem, in 2000? In 1993, I actually established a bone…
Address: Seongnam jungwongu beltway 210 (sangdaewondong) 101
Tel: (031)-732-1555
Web: http://www.seoulcord.co.kr/index1.asp
Histostem is a stem cell provider, specializing in the MLPCs (Multi-Lineage Progenitor Cells) research, the treatment of disease and injury, and the banking of stem cells. Stem cells are the body’s “master” cells because they give rise to all other tissues, organs, and systems in the body. The stemcells’ ability to differentiate, or change, into other types of cells in the body, is a fairly new discovery that holds tremendous promise for treating and curing some of the most common diseases such as heart diseases, cancers, stroke, paralysis, liver cirrhosis, Buerger’s and Alzheimer’s diseases. What’s more, this treatment is not years away. Histostem is already using hematopoietic stemcells taken from UCB to treat blood diseases such as various kinds of leukemia, multiple sclerosis, amyotrophic lateral sclerosis, etc. Histostem also succeeded in extracting non-hematopoietic multipotent stem cells from UCB in their most pure state and perfected in multiplying and cultivating those stemcells. Histostem is the world’s first runner in applying our stem cell therapy to human patients, and currently using our stem cells to treat with great success such illnesses as Buerger’s disease, Type II diabetes, liver cirrhosis, paralysis after spinal cord injury, osteoporosis, chronic renal failure, and Alzheimer’s disease, to name a few. Finally, in order to achieve the most effective donor matching of cord blood to patient, our research technicians are busy typing the human leukocyte antigens (HLA) in our biogenetics laboratory.
Stem cell provider, specializing in the MLPCs (Multi-Lineage Progenitor Cells) research, the treatment of disease and injury, and the banking of stem cells.
After spending a large part of your career as a university professor, what drove you to create your own company, Histostem, in 2000? In 1993, I actually established a bone…
National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of…
Seung-Kyou Lee, vice-president of Korea Bio gives his assessment on the current landscape for biotech firms in Korea. He also discusses Korea Bio’s programme to create a further 1000 biotech…
Young-Whan Park, president of National OncoVenture, discusses their programme to support oncology drug development in South Korea, with a view to discovering and producing a globally competitive, Korean-made oncology medicine.…
Christoph Heider, president of the European Chamber of Commerce in Korea (ECCK), discusses the organization, the need for the modernization of the Europe-South Korea Free Trade Agreement, and the future…
Southeast Asia’s notoriously strict anti-cannabis laws could be set to relax dramatically as South Korea becomes the first country in the region to legalise cannabis for medicinal use. This…
Sunyoung Kim, CEO and founder of ViroMed, reveals his strategy for conquering the US market and the feasibility of his ambitions for ViroMed to become the biotech company with the…
In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of…
Professor Dukgeun Ahn of Seoul National University, trade policy advisor to the Ministry of Health offers his insights into the current policies towards the healthcare industry in Korea, and the…
South Korea’s proposed Moon Jae-In Care has been subject to both praise and protest this year. President Moon Jae-in’s plan dubbed “Moon Care” will be implemented in stages throughout 2022…
Jongmoon Kim, CEO of ToolGen discusses the potential for their CRISPR technology to revolutionize not only therapy for genetic illnesses, but also agriculture. Kim explains his move from information technology…
JungTae Park, senior managing director of KoBIA (Korea Biomedicine Industry Association), describes the achievements of the association as a bridge between industry and government. He also highlights the potential of…
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
See our Cookie Privacy Policy Here
